# Keuro Medtech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/keuro-medtech

- Industry: Medical Devices & Equipment
- Headquarters: Shanghai, China
- Website: www.keuromedtech.com/
- Total disclosed funding: $118M
- Latest round: Series D (Jul 28, 2026)
- Investors on record: 17

## About

Based in Shanghai, China and founded in 2019, Shanghai Lee Kai Technology Co., Ltd., dba Keuro Medtech, is a medical device manufacturer that focuses on neurological intervention surgery. The CEO, An Liu worked at Medtronic, Inc. and NAMSA. The company has set up an innovation center in Hangzhou, a research and development center in California, and a branch office in Berlin. In July 2021, the company launched the first product, intracranial distal access catheter. In July 2026, Keuro Medtech raised nearly CNY 500 million in series D funding co-led by Shanghai STVC Group and Shanghai Minhang Financial Investment Development, with participation from Tppoly Capital, NTG Tongshang Holding Group, Huatai Zijin Investment, Shanghai Waigaoqiao Free Trade Zone Group Co., Ltd., Shenzhen Capital Real Estate Fund and other investors.

The company focuses on the research, development, production and sales of neurological intervention surgery implanted medical device products. Its main self-developed products include intracranial guide wire, intracranial microcatheter, intracranial delivery catheter, intracranial suction catheter and intracranial mechanical embolization. Lee Kai also provides stroke diagnosis and rehabilitation service for customers.

The company's revenue is generated from sales of neuro-interventional and implantable medical devices. 

The company will use the latest funding for three major development directions: first, increasing investment in innovative product R&D and clinical trials, while continuing to deepen its expertise in the neurointerventional field, and gradually expanding into peripheral intervention, oncology intervention, and other tracks; second, supplementing its end-user therapeutic product pipeline through mergers and acquisitions, seizing market opportunities brought by centralized procurement, rapidly enriching its product matrix, and forming a diversified growth model of "stable volume growth of channel products, improved gross profit of therapeutic products, and continuous follow-up of innovative products"; third, promoting capacity building and international business expansion, further deploying production bases to meet the demand for large-scale mass production, while leveraging its CDMO business in the US and Europe and its global business cooperation network to actively undertake global opportunities for the transfer of R&D and manufacturing of high-value consumables.

## Funding rounds

- Series D, Jul 28, 2026, $74M — Shanghai STVC Group, Huatai Zijin Investment, Shenzhen Capital Real Estate Fund, Tppoly Capital, Shanghai Waigaoqiao Free Trade Zone Group Co., Ltd., NTG Tongshang Holding Group, Shanghai Minhang Financial Investment Development
- Series D, Feb 2, 2026 — Shanghai Guoxin Venture Capital Investment, Guolian Jintou Hehe Fund
- Series C, Jan 5, 2024 — Wuxi Huading Venture Capital, Shanghai Guoxin Venture Capital Investment
- Series B, Mar 14, 2022, $32M — Shenzhen Capital Real Estate Fund, Linchuang Capital
- Series B, Aug 12, 2021 — Tigermed, Hengxu Capital, Sunmed Capital
- Series A, Jun 1, 2020, $13M — TF Capital, TigerYeah Capital, Zhiyang Capital, Sunmed Capital

## Investors

- TF Capital — Series A
- TigerYeah Capital (https://capitalatlas.ai/funds/tigeryeah-capital) — Series A
- Zhiyang Capital — Series A
- Sunmed Capital (https://capitalatlas.ai/funds/sunmed-capital) — Series A, Series B
- Tigermed (https://capitalatlas.ai/funds/tigermed) — Series B
- Hengxu Capital (https://capitalatlas.ai/funds/hengxu-capital) — Series B
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series B, Series D
- Linchuang Capital (https://capitalatlas.ai/funds/linchuang-capital) — Series B
- Wuxi Huading Venture Capital (https://capitalatlas.ai/funds/wuxi-huading-venture-capital) — Series C
- Shanghai Guoxin Venture Capital Investment — Series C, Series D
- Guolian Jintou Hehe Fund (https://capitalatlas.ai/funds/guolian-jintou-hehe-fund) — Series D
- Shanghai STVC Group (https://capitalatlas.ai/funds/shanghai-stvc-group) — Series D
- Huatai Zijin Investment (https://capitalatlas.ai/funds/huatai-zijin-investment) — Series D
- Tppoly Capital (https://capitalatlas.ai/funds/tppoly-capital) — Series D
- Shanghai Waigaoqiao Free Trade Zone Group Co., Ltd. — Series D
- NTG Tongshang Holding Group — Series D
- Shanghai Minhang Financial Investment Development — Series D